

Brent L Wood

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1155829/brent-l-wood-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

10,293
citations

45
h-index

100
g-index

200
ext. papers

12,980
ext. citations

5
avg, IF

6.04
L-index

#	Paper	IF	Citations
192	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101755	2.2	4
191	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.. <i>Cancer</i> , 2022 ,	6.4	2
190	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101766	2.2	4
189	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102678	2.2	3
188	Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.. <i>Current Protocols</i> , 2022 , 2, e383		1
187	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.. <i>HemaSphere</i> , 2022 , 6, e676	0.3	3
186	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021 , 138, 2382-2382	2.2	
185	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 3487-3487	2.2	
184	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 614-614	2.2	
183	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 256-256	2.2	1
182	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101405	2.2	7
181	Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO. <i>Blood</i> , 2021 , 138, 4475-4475	2.2	
180	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021 , 138, 3398-3398	2.2	1
179	Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States. <i>Blood</i> , 2021 , 138, 4478-4478	2.2	
178	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. <i>Advances in Molecular Pathology</i> , 2021 , 4, 49-63	0.3	
177	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. <i>Blood</i> , 2021 ,	2.2	33
176	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1226-1233	1.9	7

175	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10004-10004	2.2	1
174	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1437-1447	2.2	10
173	Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1540-1552	2.2	4
172	Pre-B cell receptor expression in B-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19006-e19006	2.2	
171	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10002-10002	2.2	
170	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10003-10003	2.2	
169	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. <i>Blood</i> , 2021 , 137, 569-572	2.2	9
168	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28574	3	2
167	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 408-417	9.7	7
166	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28929	3	0
165	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29256	3	1
164	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2628-2638	2.2	9
163	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3062-3070	2.2	22
162	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. <i>Leukemia</i> , 2020 , 34, 2479-2483	10.7	6
161	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020 , 34, 1577-1587	10.7	10
160	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020 , 136, 44-45	2.2	1
159	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020 , 136, 38-40	2.2	
158	Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020 , 136, 15-15	2.2	2

157	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020 , 136, 38-39	2.2	
156	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020 , 130, 863-876	15.9	21
155	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. <i>Blood</i> , 2020 , 136, 45-46	2.2	3
154	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-L): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020 , 136, 11-12	2.2	8
153	Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. <i>Blood</i> , 2020 , 136, 11-12	2.2	5
152	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10510-10510	2.2	1
151	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10509-10509	2.2	1
150	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 669-672	4.4	4
149	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020 , 126, 593-601	6.4	18
148	Flow cytometric features of incidental indolent T lymphoblastic proliferations. <i>Cytometry Part B - Clinical Cytometry</i> , 2020 , 98, 282-287	3.4	5
147	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020 , 43, 100650	11.1	8
146	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020 , 34, 1701-1705	10.7	3
145	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020 , 38, 602-612	2.2	52
144	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020 , 12,	6.6	12
143	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3282-3293 ²	3.2	51
142	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. <i>Biomarker Research</i> , 2020 , 8, 29	8	6
141	Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. <i>Current Protocols in Cytometry</i> , 2020 , 93, e73	3.6	14
140	Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019 , 134, 1585-1597	2.2	120

139	Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2019 , 96, 256-265	3.4	28
138	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019 , 104, e517-e520	6.6	7
137	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. <i>Cytometry Part B - Clinical Cytometry</i> , 2019 , 96, 300-309	3.4	4
136	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27681	3	3
135	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019 , 238, 62-68	2.3	21
134	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. <i>Blood</i> , 2019 , 134, 824-824	2.2	4
133	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. <i>Blood</i> , 2019 , 134, 2729-2729	2.2	1
132	Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 204-204	2.2	42
131	Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase. <i>Blood</i> , 2019 , 134, 1856-1856	2.2	8
130	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10033-10033	2.2	
129	Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2019 , 134, 1475-1475	2.2	1
128	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019 , 134, 2691-2691	2.2	
127	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019 , 134, 321-321	2.2	
126	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. <i>Blood</i> , 2019 , 134, 286-286	2.2	
125	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 649-649	2.2	2
124	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019 , 134, 2692-2692	2.2	
123	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1511-1514	4.4	1
122	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. <i>Methods in Molecular Biology</i> , 2019 , 1956, 35-60	1.4	3

121	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019 , 104, 986-992	6.6	12
120	Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. <i>Cytometry Part B - Clinical Cytometry</i> , 2019 , 96, 67-72	3.4	14
119	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019 , 51, 296-307	36.3	189
118	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019 , 33, 554-558	10.7	6
117	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019 , 133, 724-729	2.2	29
116	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018 , 32, 1370-1379	10.7	25
115	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1615-1620	4.7	20
114	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018 , 32, 2126-2137	10.7	38
113	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018 , 124, 1150-1159	6.4	18
112	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018 , 131, 1350-1359	2.2	108
111	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 956-963	4.7	12
110	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018 , 131, 1275-1291	2.2	528
109	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018 , 131, 995-999	2.2	112
108	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018 , 93, 546-552	7.1	7
107	A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 112-120	3.4	50
106	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018 , 132, 815-824	2.2	58
105	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018 , 132, 1000-1000	2.2	1
104	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018 , 132, 35-35	2.2	6

103	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1011-1011	2.2	62
102	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10500-10500	2.2	46
101	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 565-565	2.2	1
100	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018 , 132, 5255-5255	2.2	
99	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018 , 132, 3978-3978	2.2	
98	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018 , 132, 889-889	2.2	
97	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018 , 132, 659-659	2.2	
96	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018 , 16, 42-52	2.1	5
95	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2306-2314	2.2	119
94	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018 , 36, 591-599	2.2	85
93	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky069	4.6	7
92	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018 , 215, 3094-3114	16.6	26
91	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2926-2934	2.2	95
90	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 691-696	4.7	30
89	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017 , 102, 865-873	6.6	132
88	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017 , 376, 836-847	59.2	978
87	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017 , 129, 3352-3361	2.2	168
86	Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, e170580	13.4	248

85	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. <i>Haematologica</i> , 2017 , 102, 1549-1557	6.6	19
84	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2717-2719	1.9	7
83	Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. <i>American Journal of Pathology</i> , 2017 , 187, 304-317	5.8	8
82	Methods of Detection of Measurable Residual Disease in AML. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 557-567	4.4	22
81	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2527-2534	2.2	43
80	How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 237-248	4.2	11
79	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017 , 49, 1211-1218	36.3	430
78	Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. <i>Blood Reviews</i> , 2017 , 31, 63-75	11.1	92
77	Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. <i>Blood</i> , 2017 , 130, 811-811	2.2	76
76	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2016 , 172, 134-6	4.5	5
75	Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2016 , 90, 47-53	3.4	80
74	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016 , 7, 13331	17.4	128
73	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , 2016 , 8, 355ra116	17.5	613
72	Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2016 , 90, 387-92	3.4	3
71	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-36	2.2	270
70	CD44 promotes chemoresistance in T-ALL by increased drug efflux. <i>Experimental Hematology</i> , 2016 , 44, 166-71.e17	3.1	21
69	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016 , 128, 1086-1086 ²	2.2	2
68	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 211-211	2.2	21

67	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 340-340	2.2	4
66	Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 102-102	2.2	18
65	The value of secondary pathology review.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7-7	2.2	1
64	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016 , 128, 2890-2890	2.2	
63	Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1667-70	3	5
62	Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2109-18	1.9	17
61	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1227-1233	4.7	24
60	Clinical Experience With Modified, Single-Tube T-Cell Receptor V β Flow Cytometry Analysis for T-Cell Clonality. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 467-85	1.9	9
59	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2380-8	2.2	219
58	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 944-53	59.2	247
57	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e97-8	6.6	8
56	Flow cytometry in the diagnosis and monitoring of acute leukemia in children. <i>Journal of Hematopathology</i> , 2015 , 8, 191-199	0.4	6
55	Human B-cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data. <i>Cytometry Part B - Clinical Cytometry</i> , 2015 , 88, 214-26	3.4	14
54	Computer-aided detection of rare tumor populations in flow cytometry: an example with classic Hodgkin lymphoma. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 517-24	1.9	3
53	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015 , 126, 964-71	2.2	217
52	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1176-83	3	65
51	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , 2015 , 126, 184-184	2.2	36
50	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2569-2569	2.2	1

49	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 3773-3773	2.2	29
48	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015 , 126, 807-807	2.2	4
47	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10006-10006	2.2	7
46	Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3006-3006	2.2	14
45	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18031-e18031	2.2	
44	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , 2015 , 126, 2571-2577		
43	Pathophysiology of Macrocytic Anemia in Diamond Blackfan Anemia and Del(5q) Myelodysplastic Syndrome. <i>Blood</i> , 2015 , 126, 670-670	2.2	
42	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 549-55	4.7	38
41	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 56-67	5.1	203
40	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3874-82	2.2	66
39	Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014 , 4, 1074-87	24.4	146
38	Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. <i>Clinical Cancer Research</i> , 2014 , 20, 4540-8	12.9	110
37	No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. <i>Experimental Hematology</i> , 2014 , 42, 497-504	3.1	1
36	Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. <i>Modern Pathology</i> , 2014 , 27, 1438-46	9.8	45
35	Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Leukemia Research and Treatment</i> , 2014 , 2014, 421723		48
34	Plasma polychlorinated biphenyl concentrations and immune function in postmenopausal women. <i>Environmental Research</i> , 2014 , 131, 174-80	7.9	6
33	Flow cytometric monitoring of residual disease in acute leukemia. <i>Methods in Molecular Biology</i> , 2013 , 999, 123-36	1.4	50
32	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013 , 45, 1494-8	36.3	205

31	Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013 , 84, 315-23	3.4	111
30	Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims. <i>Cytometry Part B - Clinical Cytometry</i> , 2013 , 84, 282-5	3.4	42
29	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013 , 122, 1813-21	2.2	264
28	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013 , 122, 2550-2550	2.2	1
27	Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. <i>Blood</i> , 2013 , 122, 882-882	2.2	2
26	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. <i>Blood</i> , 2013 , 122, 1341-1341	2.2	
25	Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm. <i>Blood</i> , 2013 , 122, 2614-2614	2.2	
24	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013 , 122, 1317-1317	2.2	
23	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012 , 481, 157-63	50.4	1163
22	The Myeloproliferative Neoplasms 2012 , 315-330		
21	Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. <i>Cancer Prevention Research</i> , 2012 , 5, 492-497	3.2	675
20	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 1418-1418	2.2	2
19	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012 , 120, 655-655	2.2	
18	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. <i>Blood</i> , 2012 , 120, 1440-1440	2.2	
17	Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 3551-3551	2.2	
16	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 341-50	4.7	80
15	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009 , 114, 1580-1580	2.2	6
14	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction. Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009 , 114, 9-9	2.2	14

13	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009 , 114, 2658-2658 ^{2,2} ⁰		
12	Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.. <i>Blood</i> , 2007 , 110, 159-159	2.2	8
11	9-color and 10-color flow cytometry in the clinical laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2006 , 130, 680-90	5	115
10	Identification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical Hodgkin Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.. <i>Blood</i> , 2006 , 108, 2262-2262	2.2	
9	A Characterization of Microparticles in Stored Packed Red Blood Cell Units.. <i>Blood</i> , 2006 , 108, 4147-4147 ^{2,2}		
8	Four-Color Flow Cytometry Shows Strong Concordance With Bone Marrow Morphology and Cytogenetics in the Evaluation for Myelodysplasia. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 170-181	1.9	96
7	Expansion of Genetically Modified Primary Human Hematopoietic Cells Using a Cell Growth Switch.. <i>Blood</i> , 2005 , 106, 3044-3044	2.2	
6	Multicolor immunophenotyping: human immune system hematopoiesis. <i>Methods in Cell Biology</i> , 2004 , 75, 559-76	1.8	61
5	In Vivo Expansion of Transduced Human Erythroid Cells Using an Mpl-Based Cell Growth Switch.. <i>Blood</i> , 2004 , 104, 2100-2100	2.2	
4	Four-Color Flow Cytometry Identifies Virtually All Cytogenetically Abnormal Bone Marrow Samples in the Workup of Non-CML Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2003 , 120, 854-865	1.9	36
3	T-cell clonality determination using polymerase chain reaction (PCR) amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled PCR products. <i>American Journal of Clinical Pathology</i> , 2000 , 113, 838-50	1.9	48
2	CD44H and CD44V6 expression in different subtypes of Hodgkin lymphoma. <i>Modern Pathology</i> , 2000 , 13, 1121-7	9.8	3
1	A phase I/II trial of iodine-131Eositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000 , 96, 2934-2942	2.2	6